Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 41: 672-678, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Crofton, P. M.
Right arrow Articles by Kelnar, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crofton, P. M.
Right arrow Articles by Kelnar, C. J.

Clinical Chemistry, Vol 41, 672-678, Copyright © 1995 by American Association for Clinical Chemistry

Bone alkaline phosphatase and height velocity in short normal children undergoing growth-promoting treatments: longitudinal study

PM Crofton, HF Stirling and CJ Kelnar
Department of Paediatric Biochemistry, Royal Hospital for Sick Children, Edinburgh, UK.

We studied the temporal and quantitative relation between bone alkaline phosphatase (ALP) and height velocity in 62 short normal children as part of a prospective randomized study to compare placebo, growth hormone, oxandralone, and testosterone, singly and in combination, in promoting short-term growth acceleration and increased final height. The pretreatment cross-sectional correlation between bone ALP and height velocity was poor (P > or = 0.25), but was much higher (P = 0.0001) 3 months after treatment started. In each treatment group, there was a parallel relation between bone ALP and height velocity through time. Individual children showed a variety of growth responses over 12-42 months, but in almost all cases bone ALP paralleled height velocity. Within individual children, bone ALP was strongly correlated with 6-month height velocity (r > 0.9 in 30% of the children, r > 0.7 in 70%). We conclude that bone ALP is a useful short-term marker of growth in short normal children treated with growth hormone.


The following articles in journals at HighWire Press have cited this article:


Home page
 JBJSHome page
J. O. Sanders, R. H. Browne, S. J. McConnell, S. A. Margraf, T. E. Cooney, and D. N. Finegold
Maturity Assessment and Curve Progression in Girls with Idiopathic Scoliosis
J. Bone Joint Surg. Am., January 1, 2007; 89(1): 64 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
F. Rauch, M. Georg, A. Stabrey, C. Neu, W. F. Blum, T. Remer, F. Manz, and E. Schoenau
Collagen Markers Deoxypyridinoline and Hydroxylysine Glycosides: Pediatric Reference Data and Use for Growth Prediction in Growth Hormone-deficient Children
Clin. Chem., February 1, 2002; 48(2): 315 - 322.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
N. S. Glaser, A. C. Shirali, D. M. Styne, and K. L. Jones
Acid-base Homeostasis in Children With Growth Hormone Deficiency
Pediatrics, December 1, 1998; 102(6): 1407 - 1414.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Tobiume, S. Kanzaki, S. Hida, T. Ono, T. Moriwake, S. Yamauchi, H. Tanaka, and Y. Seino
Serum Bone Alkaline Phosphatase Isoenzyme Levels in Normal Children and Children with Growth Hormone (GH) Deficiency: A Potential Marker for Bone Formation and Response to GH Therapy
J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2056 - 2061.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.